Curis
Update in progressCRIS (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Curis, Inc. is a Lexington, Massachusetts biotechnology company focused on discovering and developing cancer therapies. Its pipeline includes Emavusertib, an oral IRAK4 inhibitor in a Phase 1/2 trial for relapsed/refractory CNS lymphoma; Fimepinostat, an HDAC/PI3K inhibitor for relapsed/refractory DLBCL; CA-170, a PD-L1/VISTA antagonist; and CA-327, a PD-L1/TIM-3 antagonist. It collaborates with Genentech/Roche on Erivedge for advanced BCC and with Aurigene on IO and precision oncology programs. Established 2000.
Company score
- Sentiment
- 0.41
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.13
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.23
- Governance
- 0.09
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.27
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Loading section